基于面板的RNA融合测序改善儿童急性髓系白血病的诊断
该研究分析了RNA融合测序(RNA-FS)对241例儿童急性髓系白血病(AML)初始诊断的影响,发现与经典细胞遗传学(CCG)相比,RNA-FS能可靠检测风险相关融合基因,并使25例(10.4%)患者的风险分层得到改善,还将可进行可测量残留病(MRD)监测的患者比例从44.4%提高至75.5%。
要点
- RNA-FS可可靠检测儿童AML中风险相关融合基因。
- RNA-FS使25例(10.4%)患者风险分层改善。
- RNA-FS将可进行MRD监测的患者比例从44.4%提高至75.5%。
核心结论
- 与经典细胞遗传学相比,RNA-FS能可靠检测儿童AML中风险相关融合基因,并改善风险分层和MRD监测可行性。
研究设计与样本
- 对241例儿童急性髓系白血病(AML)患者的初始诊断进行分析,比较RNA融合测序(RNA-FS)与经典细胞遗传学(CCG)的效果。
主要发现
- RNA-FS与经典细胞遗传学相比,能可靠检测儿童AML中风险相关融合基因。
- RNA-FS显著改善了对NUP98::NSD1、KMT2A::MLLT10和CBFA2T3::GLIS2等隐匿性融合基因的检测,使25例(10.4%)患者风险分层改善。
- 验证额外检测到的非风险相关高置信度融合识别出PIM3::BRD1、C22orf34::BRD1、PSPC1::ZMYM2和ARHGAP26::NR3C1为常见遗传变异,MYB::GATA1为复发性异常,首次在AML亚型M0和M7中描述。
- RNA-FS未能检测到MNX1::ETV6和其他12p染色体异常等经细胞遗传学确认的罕见融合事件。
- 作为附加益处,RNA-FS使可进行可测量残留病(MRD)监测的患者比例从44.4%提高至75.5%。
局限性
- RNA-FS未能检测到MNX1::ETV6和其他12p染色体异常等经细胞遗传学确认的罕见融合事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New methods like panel-based RNA fusion sequencing (RNA-FS) promise improved diagnostics in various malignancies. We here analyzed the impact of RNA-FS on the initial diagnostics of 241 cases with pediatric acute myeloid leukemia (AML). We show that, compared to classical cytogenetics (CCG), RNA-FS reliably detected risk-relevant fusion genes in pediatric AML. In addition, RNA-FS strongly improved the detection of cryptic fusion genes like NUP98::NSD1, KMT2A::MLLT10 and CBFA2T3::GLIS2 and thereby resulted in an improved risk stratification in 25 patients (10.4%). Validation of additionally detected non-risk-relevant high confidence fusion calls identified PIM3::BRD1, C22orf34::BRD1, PSPC1::ZMYM2 and ARHGAP26::NR3C1 as common genetic variants and MYB::GATA1 as recurrent aberration, which we here describe in AML subtypes M0 and M7 for the first time. However, it failed to detect rare cytogenetically confirmed fusion events like MNX1::ETV6 and other chromosome 12p-abnormalities. As add-on benefit, the proportion of patients for whom measurable residual disease (MRD) monitoring became possible was increased by RNA-FS from 44.4 to 75.5% as the information on the fusion transcripts' sequence allowed the design of new MRD assays.
引用
- Hoffmeister LM, Suttorp J, Walter C, et al. Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia. Leukemia. 2023. PMID: 38086945. doi:10.1038/s41375-023-02102-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。